Transdermal NSAID Report 2026-2032: Arthritis/Muscle Pain, Reduced GI Side Effects & Asia Growth
公開 2026/04/07 16:59
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Ketoprofen Transdermal Patch - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ketoprofen Transdermal Patch market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Ketoprofen Transdermal Patch was estimated to be worth US$ 396 million in 2025 and is projected to reach US$ 544 million, growing at a CAGR of 4.7% from 2026 to 2032. Ketoprofen transdermal patch is a topical non-steroidal anti-inflammatory drug (NSAID) formulation designed to deliver ketoprofen directly through the skin to reduce localized pain and inflammation. It is commonly used for conditions such as arthritis, muscle strain, back pain, and sports injuries. Compared with oral NSAIDs, the patch minimizes systemic exposure and side effects, particularly gastrointestinal irritation. The patch provides sustained drug release over 12 to 24 hours and is appreciated for its convenience, better patient compliance, and localized action. Ketoprofen patches are available in both prescription and over-the-counter forms in many countries.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091346/ketoprofen-transdermal-patch
1. Core Advantages: Localized Action, Reduced GI Side Effects & Sustained Release
The ketoprofen transdermal patch market is built upon three critical advantages over oral NSAIDs: localized action (delivers drug directly to pain site), reduced GI side effects (minimizes systemic exposure, avoiding gastric ulcers), and sustained release (12-24 hour dosing). Unlike oral ketoprofen (associated with 15-20% GI adverse event rate), transdermal patches provide therapeutic local concentrations with 90% lower systemic exposure. Since Q4 2025, new hydrogel and matrix patch technologies have improved drug release profiles and wear comfort, driving adoption among elderly patients (polymedicated, GI risk).
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across patch types and distribution channels:
By Type (Patch Technology):
Hydrogel Patch holds approximately 45% of market revenue, preferred for high water content (60-80%), excellent skin adhesion, and cooling sensation (soothes inflammation).
Polymer Matrix Controlled-Release Patch accounts for 35%, offering zero-order release kinetics (constant drug delivery over 24 hours) and longer wear time.
Self-Adhesive Nonwoven Patch holds 20%, lower cost but less sophisticated release profile.
By Application (Distribution Channel):
Hospitals and Clinics (prescription, post-surgical, chronic pain management) leads with 55% of revenue.
Retail Pharmacies (OTC, self-medication) accounts for 35%, fastest-growing at 6% CAGR.
Online Pharmacies (home delivery, chronic condition refills) holds 10%, growing at 8% CAGR.
Regional Breakdown:
Japan (most mature market): 35% share, driven by aging population (29% over 65), reimbursement coverage, and dominance of Hisamitsu/Teikoku Seiyaku.
Europe (France, Italy, Spain): 30% share, moderate-to-high penetration, well-accepted for chronic musculoskeletal conditions.
China and Asia-Pacific: 20% share, fastest-growing at 10% CAGR, driven by generic entry and increasing acceptance in hospitals/retail pharmacies.
North America: 10% share, limited due to regulatory restrictions and preference for diclofenac patches (Voltaren).
Rest of World: 5% share, emerging markets (Latin America, Middle East) with low penetration but growth potential.
The Ketoprofen Transdermal Patch market is segmented as below:
By Company: Hisamitsu Pharmaceutical, Teikoku Seiyaku, Handok, Kyorin Pharmaceutical, Yutoku Yakuhin, Nichi-Iko Pharmaceutical, Abiogen Pharma, Sanwa Kagaku Kenkyusho, Wooshin Medics, Jeil Pharmaceutical, Emcure Pharmaceuticals, Towa Pharmaceutical, Nihon Generic, Guizhou Liansheng Pharmaceutical, Jiudian Pharmaceutical
Segment by Type: Hydrogel Patch, Polymer Matrix Controlled-Release Patch, Self-Adhesive Nonwoven Patch
Segment by Application: Hospitals and Clinics, Retail Pharmacies, Online Pharmacies
3. Technical Deep Dive: Drug Release Kinetics, Skin Permeation & Adhesion
A persistent technical challenge across all ketoprofen patches is drug release kinetics (zero-order vs first-order), skin permeation enhancement (penetration enhancers), and adhesion durability (24-hour wear without detachment).
Recent innovations addressing these issues include:
Hydrogel patches with enhanced permeation (Hisamitsu, Teikoku) using propylene glycol and ethanol as penetration enhancers, achieving 2-3x higher skin flux vs first-generation patches.
Matrix patches with rate-controlling membrane (Kyorin, Yutoku) achieving zero-order release (constant drug delivery) for 24 hours, maintaining therapeutic plasma levels (10-50 ng/mL).
Acrylic-based adhesives (Nichi-Iko, Wooshin) providing 24-hour adhesion with low skin irritation (patch removal force 2-5 N), improving patient compliance.
Generics entry (China, India) with bioequivalence studies (PK parameters Cmax, AUC within 80-125% of reference), driving price competition and market expansion.
Exclusive observation: Unlike oral NSAIDs (rapid absorption, peak plasma concentration 1-2 hours), transdermal ketoprofen provides low, sustained plasma levels (5-20 ng/mL) while achieving high local tissue concentrations (500-2000 ng/g in muscle/joint). This "systemic low, local high" profile reduces GI risk (COX-1 sparing) while maintaining efficacy. Key penetration enhancers: (1) propylene glycol (2-5%), (2) ethanol (5-10%), (3) oleic acid (1-3%). Hisamitsu's "Mohrus" patch (hydrogel, 20mg ketoprofen) dominates Japanese market (60% share). China's domestic generics (Guizhou Liansheng, Jiudian) have 40% lower price ($0.50 vs $0.80 per patch) but variable bioequivalence data. The growth driver is aging population (Japan 29% over 65, Europe 20-25%, China 15% and rising) with chronic musculoskeletal pain (osteoarthritis, back pain). Non-opioid pain relief demand (opioid crisis in US) may drive North America adoption, but regulatory barriers (FDA requires NDA for ketoprofen patch, while diclofenac is OTC) slow entry.
4. Industry Stratification: Japan vs. Europe vs. China vs. North America
For manufacturers and investors, market dynamics differ significantly by region:
Dimension Japan Europe (France/Italy/Spain) China North America
Market maturity Mature (saturated) Moderate Growing (fastest) Limited (nascent)
Market share (global) 35% 30% 15% (growing to 20% by 2030) 10%
Key players Hisamitsu, Teikoku, Kyorin Abiogen, Emcure Guizhou Liansheng, Jiudian (import only)
Reimbursement Yes (NHI) Partial Limited (hospitals only) No
OTC availability Yes Yes (varies by country) No (prescription) No
Price per patch (retail) $0.80-1.20 $0.70-1.00 $0.50-0.80 $1.00-1.50 (import)
CAGR (2026-2032) 2% 3% 10% 4%
Japan is mature but stable (aging population). Europe has moderate growth (non-opioid shift). China is fastest-growing (generic entry, hospital acceptance). North America is limited (diclofenac preference, regulatory barriers).
5. User Case & Policy Update
Case Study – Hisamitsu Mohrus Patch (Japan, Market Leader):
Hisamitsu's hydrogel patch (20mg ketoprofen) holds 60% share in Japan. Results: 24-hour wear, 80-90% patient satisfaction, reimbursed by NHI, 500M+ patches annually.
Case Study – European OTC Adoption (France, Italy):
Ketoprofen patches (Abiogen, Emcure) available OTC in France, Italy. Results: 30% of NSAID patch market (vs 60% for diclofenac), preferred for acute muscle pain, 15% CAGR.
Case Study – China Domestic Generic (Guizhou Liansheng):
Guizhou Liansheng generic ketoprofen patch (2019 approval). Results: 40% lower price vs Hisamitsu import ($0.50 vs $0.80), bioequivalence demonstrated (Chinese NMPA), 100M+ patches annually, 30% hospital penetration.
Policy Update (June 2026):
FDA (2025) issued draft guidance for topical NSAID patches (ketoprofen, diclofenac, flurbiprofen) requiring bioequivalence studies with skin permeation and PK endpoints.
EMA (2025) updated guideline for transdermal patches requiring adhesion testing (24-hour wear) and skin irritation studies (primary irritation index <1.0).
Japan PMDA (2025) revised reimbursement pricing for generic patches (10% reduction), encouraging generic penetration.
China's NMPA (2026) included ketoprofen patch in national volume-based procurement (VBP) list, reducing hospital price by 50% (to $0.30-0.40 per patch), accelerating volume growth.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Ketoprofen Transdermal Patch was estimated to be worth US$ 396 million in 2025 and is projected to reach US$ 544 million, growing at a CAGR of 4.7% from 2026 to 2032. Ketoprofen transdermal patch is a topical non-steroidal anti-inflammatory drug (NSAID) formulation designed to deliver ketoprofen directly through the skin to reduce localized pain and inflammation. It is commonly used for conditions such as arthritis, muscle strain, back pain, and sports injuries. Compared with oral NSAIDs, the patch minimizes systemic exposure and side effects, particularly gastrointestinal irritation. The patch provides sustained drug release over 12 to 24 hours and is appreciated for its convenience, better patient compliance, and localized action. Ketoprofen patches are available in both prescription and over-the-counter forms in many countries.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091346/ketoprofen-transdermal-patch
1. Core Advantages: Localized Action, Reduced GI Side Effects & Sustained Release
The ketoprofen transdermal patch market is built upon three critical advantages over oral NSAIDs: localized action (delivers drug directly to pain site), reduced GI side effects (minimizes systemic exposure, avoiding gastric ulcers), and sustained release (12-24 hour dosing). Unlike oral ketoprofen (associated with 15-20% GI adverse event rate), transdermal patches provide therapeutic local concentrations with 90% lower systemic exposure. Since Q4 2025, new hydrogel and matrix patch technologies have improved drug release profiles and wear comfort, driving adoption among elderly patients (polymedicated, GI risk).
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across patch types and distribution channels:
By Type (Patch Technology):
Hydrogel Patch holds approximately 45% of market revenue, preferred for high water content (60-80%), excellent skin adhesion, and cooling sensation (soothes inflammation).
Polymer Matrix Controlled-Release Patch accounts for 35%, offering zero-order release kinetics (constant drug delivery over 24 hours) and longer wear time.
Self-Adhesive Nonwoven Patch holds 20%, lower cost but less sophisticated release profile.
By Application (Distribution Channel):
Hospitals and Clinics (prescription, post-surgical, chronic pain management) leads with 55% of revenue.
Retail Pharmacies (OTC, self-medication) accounts for 35%, fastest-growing at 6% CAGR.
Online Pharmacies (home delivery, chronic condition refills) holds 10%, growing at 8% CAGR.
Regional Breakdown:
Japan (most mature market): 35% share, driven by aging population (29% over 65), reimbursement coverage, and dominance of Hisamitsu/Teikoku Seiyaku.
Europe (France, Italy, Spain): 30% share, moderate-to-high penetration, well-accepted for chronic musculoskeletal conditions.
China and Asia-Pacific: 20% share, fastest-growing at 10% CAGR, driven by generic entry and increasing acceptance in hospitals/retail pharmacies.
North America: 10% share, limited due to regulatory restrictions and preference for diclofenac patches (Voltaren).
Rest of World: 5% share, emerging markets (Latin America, Middle East) with low penetration but growth potential.
The Ketoprofen Transdermal Patch market is segmented as below:
By Company: Hisamitsu Pharmaceutical, Teikoku Seiyaku, Handok, Kyorin Pharmaceutical, Yutoku Yakuhin, Nichi-Iko Pharmaceutical, Abiogen Pharma, Sanwa Kagaku Kenkyusho, Wooshin Medics, Jeil Pharmaceutical, Emcure Pharmaceuticals, Towa Pharmaceutical, Nihon Generic, Guizhou Liansheng Pharmaceutical, Jiudian Pharmaceutical
Segment by Type: Hydrogel Patch, Polymer Matrix Controlled-Release Patch, Self-Adhesive Nonwoven Patch
Segment by Application: Hospitals and Clinics, Retail Pharmacies, Online Pharmacies
3. Technical Deep Dive: Drug Release Kinetics, Skin Permeation & Adhesion
A persistent technical challenge across all ketoprofen patches is drug release kinetics (zero-order vs first-order), skin permeation enhancement (penetration enhancers), and adhesion durability (24-hour wear without detachment).
Recent innovations addressing these issues include:
Hydrogel patches with enhanced permeation (Hisamitsu, Teikoku) using propylene glycol and ethanol as penetration enhancers, achieving 2-3x higher skin flux vs first-generation patches.
Matrix patches with rate-controlling membrane (Kyorin, Yutoku) achieving zero-order release (constant drug delivery) for 24 hours, maintaining therapeutic plasma levels (10-50 ng/mL).
Acrylic-based adhesives (Nichi-Iko, Wooshin) providing 24-hour adhesion with low skin irritation (patch removal force 2-5 N), improving patient compliance.
Generics entry (China, India) with bioequivalence studies (PK parameters Cmax, AUC within 80-125% of reference), driving price competition and market expansion.
Exclusive observation: Unlike oral NSAIDs (rapid absorption, peak plasma concentration 1-2 hours), transdermal ketoprofen provides low, sustained plasma levels (5-20 ng/mL) while achieving high local tissue concentrations (500-2000 ng/g in muscle/joint). This "systemic low, local high" profile reduces GI risk (COX-1 sparing) while maintaining efficacy. Key penetration enhancers: (1) propylene glycol (2-5%), (2) ethanol (5-10%), (3) oleic acid (1-3%). Hisamitsu's "Mohrus" patch (hydrogel, 20mg ketoprofen) dominates Japanese market (60% share). China's domestic generics (Guizhou Liansheng, Jiudian) have 40% lower price ($0.50 vs $0.80 per patch) but variable bioequivalence data. The growth driver is aging population (Japan 29% over 65, Europe 20-25%, China 15% and rising) with chronic musculoskeletal pain (osteoarthritis, back pain). Non-opioid pain relief demand (opioid crisis in US) may drive North America adoption, but regulatory barriers (FDA requires NDA for ketoprofen patch, while diclofenac is OTC) slow entry.
4. Industry Stratification: Japan vs. Europe vs. China vs. North America
For manufacturers and investors, market dynamics differ significantly by region:
Dimension Japan Europe (France/Italy/Spain) China North America
Market maturity Mature (saturated) Moderate Growing (fastest) Limited (nascent)
Market share (global) 35% 30% 15% (growing to 20% by 2030) 10%
Key players Hisamitsu, Teikoku, Kyorin Abiogen, Emcure Guizhou Liansheng, Jiudian (import only)
Reimbursement Yes (NHI) Partial Limited (hospitals only) No
OTC availability Yes Yes (varies by country) No (prescription) No
Price per patch (retail) $0.80-1.20 $0.70-1.00 $0.50-0.80 $1.00-1.50 (import)
CAGR (2026-2032) 2% 3% 10% 4%
Japan is mature but stable (aging population). Europe has moderate growth (non-opioid shift). China is fastest-growing (generic entry, hospital acceptance). North America is limited (diclofenac preference, regulatory barriers).
5. User Case & Policy Update
Case Study – Hisamitsu Mohrus Patch (Japan, Market Leader):
Hisamitsu's hydrogel patch (20mg ketoprofen) holds 60% share in Japan. Results: 24-hour wear, 80-90% patient satisfaction, reimbursed by NHI, 500M+ patches annually.
Case Study – European OTC Adoption (France, Italy):
Ketoprofen patches (Abiogen, Emcure) available OTC in France, Italy. Results: 30% of NSAID patch market (vs 60% for diclofenac), preferred for acute muscle pain, 15% CAGR.
Case Study – China Domestic Generic (Guizhou Liansheng):
Guizhou Liansheng generic ketoprofen patch (2019 approval). Results: 40% lower price vs Hisamitsu import ($0.50 vs $0.80), bioequivalence demonstrated (Chinese NMPA), 100M+ patches annually, 30% hospital penetration.
Policy Update (June 2026):
FDA (2025) issued draft guidance for topical NSAID patches (ketoprofen, diclofenac, flurbiprofen) requiring bioequivalence studies with skin permeation and PK endpoints.
EMA (2025) updated guideline for transdermal patches requiring adhesion testing (24-hour wear) and skin irritation studies (primary irritation index <1.0).
Japan PMDA (2025) revised reimbursement pricing for generic patches (10% reduction), encouraging generic penetration.
China's NMPA (2026) included ketoprofen patch in national volume-based procurement (VBP) list, reducing hospital price by 50% (to $0.30-0.40 per patch), accelerating volume growth.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ